Warrior Spirit: An Interview with Victoria Gray, Sickle Cell Pioneer
By Victoria Gray, Uduak Thomas, and Kevin Davies,
The CRISPR Journal
| 02. 14. 2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell warrior and a true pioneer in the world of CRISPR and cell therapy. That process began 4.5 years ago. Today, she is healthy, enjoying a pain-free life with her family and friends—as are dozens of other sickle cell patients who participated in the trial. In December 2023, the U.S. Food and Drug Administration (FDA) approved Casgevy, setting a list price of $2.2 million for the one-time therapy. In January 2024, Executive Editor Kevin Davies and GEN Senior Editor Uduak Thomas interviewed Gray for “The State of Cell and Gene Therapy,” a GEN virtual summit that was broadcast on January 24, 2024.
(This interview has been lightly edited for length and clarity.)
Victoria, how are you feeling today?
Gray: I'm still doing good—way better than I expected in the beginning. So life is good for me right now.
What can you...
Related Articles
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
By Aaron Ginn, The Washington Post | 09.12.2025
Earlier this year, I had dinner in D.C. with Jensen Huang, the president and chief executive of Nvidia. At one point, he said something that struck me: “Why is everyone here so negative?”
He wasn’t referring to the economy...
By Roni Caryn Rabin, The New York Times | 08.25.2025
Scientists have dreamed for centuries about using animal organs to treat ailing humans. In recent years, those efforts have begun to bear fruit: Researchers have begun transplanting the hearts and kidneys of genetically modified pigs into patients, with varying degrees...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...
